Hikma Pharmaceuticals Appeals to Supreme Court Over “Skinny Label” Patent Ruling

Hikma Pharmaceuticals USA Inc. has made a significant move by urging the U.S. Supreme Court to review a decision in a revived patent suit concerning its generic version of Amarin Pharma Inc.’s cardiovascular drug, Vascepa. The pharmaceutical company is contending that the decision undermines a law allowing “skinny labels,” which are intended to facilitate the marketing of generic drugs for non-patented uses. Hikma argues that the constraints now imposed by the revived patent suit could materially impact the availability of generic drugs, potentially affecting a wide range of such pharmaceuticals across the market. Further details on the case are accessible on Law360.